These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 20402783)

  • 1. Mutational analysis of reduced telithromycin susceptibility of Streptococcus pneumoniae isolated clinically in Japan.
    Takaya A; Kitagawa N; Kuroe Y; Endo K; Okazaki M; Yokoyama E; Wada A; Yamamoto T
    FEMS Microbiol Lett; 2010 Jun; 307(1):87-93. PubMed ID: 20402783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary.
    Zhanel GG; Johanson C; Laing N; Hisanaga T; Wierzbowski A; Hoban DJ
    Antimicrob Agents Chemother; 2005 May; 49(5):1943-8. PubMed ID: 15855517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Molecular analytical evaluation of macrolide- and ketolide-resistant Streptococcus pneumoniae--mechanism of action of telithromycin and resistance to it].
    Inoue M; Kaneko K; Nakano R; Sato Y; Arai S
    Jpn J Antibiot; 2004 Oct; 57(5):425-37. PubMed ID: 15655904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae.
    Mazzariol A; Koncan R; Vitali LA; Cornaglia G
    J Antimicrob Chemother; 2007 Jun; 59(6):1171-6. PubMed ID: 17405779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time-kill kinetics of Streptococcus pneumoniae with reduced susceptibility to telithromycin.
    Al-Lahham A; Reinert RR
    Chemotherapy; 2007; 53(3):190-3. PubMed ID: 17347565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of ermB gene transposition by Tn1545 and Tn917 in macrolide-resistant Streptococcus pneumoniae isolates.
    Okitsu N; Kaieda S; Yano H; Nakano R; Hosaka Y; Okamoto R; Kobayashi T; Inoue M
    J Clin Microbiol; 2005 Jan; 43(1):168-73. PubMed ID: 15634967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) (1998 2004).
    Wierzbowski AK; Nichol K; Laing N; Hisanaga T; Nikulin A; Karlowsky JA; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2007 Oct; 60(4):733-40. PubMed ID: 17673477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High prevalence of the ermB gene among erythromycin-resistant streptococcus pneumoniae isolates in Germany during the winter of 2000-2001 and in vitro activity of telithromycin.
    Kresken M; Henrichfreise B; Bagel S; Brauers J; Wiedemann B
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3193-5. PubMed ID: 15273149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telithromycin-nonsusceptible clinical isolates of Streptococcus pneumoniae from Europe.
    Al-Lahham A; Appelbaum PC; van der Linden M; Reinert RR
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3897-900. PubMed ID: 17065627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activities of new ketolide, telithromycin, and eight other macrolide antibiotics against Streptococcus pneumoniae having mefA and ermB genes that mediate macrolide resistance.
    Ubukata K; Iwata S; Sunakawa K
    J Infect Chemother; 2003 Sep; 9(3):221-6. PubMed ID: 14513389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative in vitro and bactericidal activities of telithromycin against penicillin-nonsusceptible, levofloxacin-resistant, and macrolide-resistant Streptococcus pneumoniae by time-kill methodology.
    Kays MB; Lisek CR; Denys GA
    Int J Antimicrob Agents; 2007 Mar; 29(3):289-94. PubMed ID: 17240118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms, molecular and sero-epidemiology of antimicrobial resistance in bacterial respiratory pathogens isolated from Japanese children.
    Sunakawa K; Farrell DJ
    Ann Clin Microbiol Antimicrob; 2007 Aug; 6():7. PubMed ID: 17697316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
    Walsh F; Carnegy F; Willcock J; Amyes S
    J Antimicrob Chemother; 2004 May; 53(5):793-6. PubMed ID: 15056640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4.
    Jenkins SG; Brown SD; Farrell DJ
    Ann Clin Microbiol Antimicrob; 2008 Jan; 7():1. PubMed ID: 18190701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model.
    Tessier PR; Mattoes HM; Dandekar PK; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2005 Jan; 49(1):188-94. PubMed ID: 15616295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotypes of macrolide-resistant pneumococci from children in southwestern Japan: raised incidence of strains that have both erm(B) and mef(A) with serotype 6B clones.
    Ikenaga M; Kosowska-Shick K; Gotoh K; Hidaka H; Koga H; Masunaga K; Nagai K; Tsumura N; Appelbaum PC; Matsuishi T
    Diagn Microbiol Infect Dis; 2008 Sep; 62(1):16-22. PubMed ID: 18068325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of resistance mechanisms and serotype and genotype distributions of macrolide-resistant strains in clinical isolates of Streptococcus pneumoniae [corrected] in Aydın, Turkey.
    Telli M; Eyigör M; Gültekin B; Aydın N
    J Infect Chemother; 2011 Oct; 17(5):658-64. PubMed ID: 21461656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial susceptibilities and distribution of resistance genes for beta-lactams and macrolides in Streptococcus pneumoniae isolated between 2002 and 2004 in Tokyo.
    Noguchi N; Tano J; Nasu Y; Koyama M; Narui K; Kamishima H; Saito T; Tsuyuki K; Sasatsu M
    Int J Antimicrob Agents; 2007 Jan; 29(1):26-33. PubMed ID: 17189091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 Pneumococci from 10 central and Eastern European countries.
    Nagai K; Appelbaum PC; Davies TA; Kelly LM; Hoellman DB; Andrasevic AT; Drukalska L; Hryniewicz W; Jacobs MR; Kolman J; Miciuleviciene J; Pana M; Setchanova L; Thege MK; Hupkova H; Trupl J; Urbaskova P
    Antimicrob Agents Chemother; 2002 Feb; 46(2):371-7. PubMed ID: 11796344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time-kill study of the activity of telithromycin against macrolide-resistant Streptococcus pneumoniae Isolates with 23S rRNA mutations and changes in ribosomal proteins L4 and L22.
    Reinert RR; Al-Lahham A
    Antimicrob Agents Chemother; 2005 Jul; 49(7):3011-3. PubMed ID: 15980387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.